John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100.
Dr. Kovach said, "We believe that LB-100, a novel anti-cancer compound, prevents cancer cells from defending themselves against standard types of cancer treatments. In pre-clinical animal models of cancer, LB-100 inhibits cancer cell growth on its own but, more importantly, it significantly enhances the killing of cancer cells by several widely used anti-cancer drugs including Temozlomide, Doxorubicin, and Docetaxel as well as radiation. In the initial Phase I trial to be conducted at a nationally recognized comprehensive cancer center, LB-100 will be evaluated alone and in combination with a standard anti-cancer drug. We hope that the improved anti-cancer activity of LB-100 combined with conventional anti-cancer treatments in animal models is borne out in the clinic without undue toxicity. If so, we believe that regimens containing LB-100 will be associated with meaningful benefit to patients with a number of different types of cancer."